StreetInsider.com News Articles

Form 8-K Abpro Holdings, Inc. For: Feb 18

Fri, 20 Feb 2026 16:16:00 -0500

si-local-file:///var/storage/secattach/20260220/26036265.html

Form 8-K Abpro Holdings, Inc. For: Feb 18

Fri, 20 Feb 2026 16:16:00 -0500

si-local-file:///var/storage/secattach/20260220/26036265.html

Form 8-K Abpro Holdings, Inc. For: Feb 05

Wed, 11 Feb 2026 16:16:00 -0500

si-local-file:///var/storage/secattach/20260211/25983548.html

Form 8-K Abpro Holdings, Inc. For: Feb 05

Wed, 11 Feb 2026 16:16:00 -0500

si-local-file:///var/storage/secattach/20260211/25983548.html

Form SCHEDULE 13G Abpro Holdings, Inc. Filed by: GOLDMAN SACHS GROUP INC

Mon, 09 Feb 2026 16:07:00 -0500

si-local-file:///var/storage/secattach/20260209/25968101.html

Form SCHEDULE 13G Abpro Holdings, Inc. Filed by: GOLDMAN SACHS GROUP INC

Mon, 09 Feb 2026 16:07:00 -0500

si-local-file:///var/storage/secattach/20260209/25968101.html

Form 8-K Abpro Holdings, Inc. For: Jan 28

Tue, 03 Feb 2026 16:16:00 -0500

si-local-file:///var/storage/secattach/20260203/25939003.html

Form 8-K Abpro Holdings, Inc. For: Jan 28

Tue, 03 Feb 2026 16:16:00 -0500

si-local-file:///var/storage/secattach/20260203/25939003.html

Form 8-K Abpro Holdings, Inc. For: Jan 16

Fri, 23 Jan 2026 16:16:00 -0500

si-local-file:///var/storage/secattach/20260123/25887295.html

Form 8-K Abpro Holdings, Inc. For: Jan 16

Fri, 23 Jan 2026 16:16:00 -0500

si-local-file:///var/storage/secattach/20260123/25887295.html

Abpro’s Lead Program ABP-102 Featured in Celltrion Presentation at the 44th Annual J.P. Morgan Healthcare Conference

Thu, 15 Jan 2026 07:00:00 -0500

Recently IND-Cleared HER2 × CD3 T-Cell Engager Highlighted by Global Biopharmaceutical Partner

BURLINGTON, Mass., Jan. 15, 2026 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (Nasdaq: ABP), a clinical-stage biotechnology company developing next-generation antibody therapeutics for solid tumors, today announced that its lead multispecific antibody oncology program, ABP-102 / CT-P72, was featured in a presentation by its global collaboration partner, Celltrion, at the 2026 J.P. Morgan Healthcare Conference.

Celltrion’s senior executives attended the conference to present the company’s latest progress in new drug development and long-term growth strategy. The presentation took place on Tuesday, January 13, 2026 at the conference

Abpro’s Lead Program ABP-102 Featured in Celltrion Presentation at the 44th Annual J.P. Morgan Healthcare Conference

Thu, 15 Jan 2026 07:00:00 -0500

Recently IND-Cleared HER2 × CD3 T-Cell Engager Highlighted by Global Biopharmaceutical Partner

Form 8-K Abpro Holdings, Inc. For: Jan 06

Tue, 06 Jan 2026 07:06:00 -0500

si-local-file:///var/storage/secattach/20260106/25809303.html

Form 8-K Abpro Holdings, Inc. For: Jan 06

Tue, 06 Jan 2026 07:06:00 -0500

si-local-file:///var/storage/secattach/20260106/25809303.html

Abpro receives FDA clearance for cancer drug trial

Tue, 06 Jan 2026 07:00:44 -0500

Abpro Holdings (NASDAQ: ABP) and Celltrion announced that the U.S. Food and Drug Administration has cleared the Investigational New Drug application for ABP-102/CT-P72, a multispecific antibody designed to treat HER2-positive solid tumors.

The FDA clearance enables a Phase 1 clinical trial to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of the drug candidate in patients with HER2-positive solid tumors. Celltrion will lead the clinical study as part of the companies' strategic collaboration.

ABP-102/CT-P72 is engineered as a HER2 × CD3 T-cell engager that targets HER2-overexpressing tumor cells while engaging cytotoxic T cells. The design aims to enhance tumor selectivity and limit

Abpro receives FDA clearance for cancer drug trial

Tue, 06 Jan 2026 07:00:44 -0500

ABP-102/CT-P72 is engineered as a HER2 × CD3 T-cell engager that targets HER2-overexpressing tumor cells while engaging cytotoxic T cells. The design aims to enhance tumor selectivity and limit

Abpro and Celltrion, Inc. Announce U.S. FDA IND Clearance for Lead Multispecific Antibody Cancer Candidate ABP-102 / CT-P72

Tue, 06 Jan 2026 07:00:00 -0500

FDA clearance enables initiation of Abpro’s first clinical-stage solid tumor program

Clinical trial anticipated to commence in the first half of 2026 through Abpro’s global collaboration with Celltrion

BURLINGTON, Mass. and INCHEON, South Korea, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (Nasdaq: ABP), a biotechnology company developing next-generation antibody therapeutics for solid tumors, today announced, together with its co-development partner Celltrion, Inc., that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for ABP-102 / CT-P72, Abpro’s lead multispecific antibody oncology program.

The IND clearance

Abpro and Celltrion, Inc. Announce U.S. FDA IND Clearance for Lead Multispecific Antibody Cancer Candidate ABP-102 / CT-P72

Tue, 06 Jan 2026 07:00:00 -0500

FDA clearance enables initiation of Abpro’s first clinical-stage solid tumor program

Clinical trial anticipated to commence in the first half of 2026 through Abpro’s global collaboration with Celltrion

The IND clearance

Form 8-K Abpro Holdings, Inc. For: Dec 15

Mon, 15 Dec 2025 07:16:00 -0500

si-local-file:///var/storage/secattach/20251215/25737679.html

Form 8-K Abpro Holdings, Inc. For: Dec 15

Mon, 15 Dec 2025 07:16:00 -0500

si-local-file:///var/storage/secattach/20251215/25737679.html

Form 8-K Abpro Holdings, Inc. For: Dec 09

Tue, 09 Dec 2025 07:08:00 -0500

si-local-file:///var/storage/secattach/20251209/25714888.html

Form 8-K Abpro Holdings, Inc. For: Dec 09

Tue, 09 Dec 2025 07:08:00 -0500

si-local-file:///var/storage/secattach/20251209/25714888.html

Abpro receives NASDAQ listing extension to regain compliance

Tue, 09 Dec 2025 07:00:56 -0500

Abpro Holdings Inc. (NASDAQ: ABP) received formal notification from the Nasdaq Hearings Panel granting an extension to allow additional time to regain full compliance with Nasdaq listing requirements, according to a company statement.

The biotechnology company completed a reverse stock split on November 3 as part of its compliance plan. Abpro's roadmap includes a market transfer application and planned capital strategy to increase stockholders' equity to maintain listing compliance.

The company has access to up to $44 million in equity financing to fund operations and achieve financial milestones. Abpro reported achieving approximately 60% reduction in operating expenses compared to the prior year

Abpro Granted Nasdaq Listing Extension to Pursue Compliance and Strategic Objectives

Tue, 09 Dec 2025 07:00:00 -0500

Continued listing reflects progress on turnaround strategy and pipeline advancement

BURLINGTON, Mass., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (Nasdaq: ABP) (“Abpro” or the “Company”), a biotechnology company advancing next-generation antibody therapies, today announced that it has received formal notification from the Nasdaq Hearings Panel granting the Company an extension to allow additional time to regain full compliance with Nasdaq listing requirements.

“We view this extension as a recognition that our compliance plan merits continued evaluation as we work to stabilize our business and build lasting momentum,” said Miles Suk, Chief Executive Officer

Abpro Granted Nasdaq Listing Extension to Pursue Compliance and Strategic Objectives

Tue, 09 Dec 2025 07:00:00 -0500

Continued listing reflects progress on turnaround strategy and pipeline advancement